Our People Make a Difference

We Are Experienced, Dedicated, and Collegial

We are an experienced and accomplished scientific and development team who have filed multiple investigational new drug applications (INDs) and taken both small molecules and biologic products through to FDA approval and commercialization. Supporting our efforts is a strong team of founders and esteemed scientific collaborators who have published extensively and hold patents in this area of research.

Leadership

David J. Woodhouse, Ph.D.

Chief Executive Officer

David J. Woodhouse, Ph.D. has over 23 years of experience in the biopharmaceutical industry, as a scientist and expert in strategy, finance, and capital development for growing biotechnology companies. He currently serves as the Chief Executive Officer and member of the Board of Directors at Nuvig Therapeutics. Prior to Nuvig, he was Chief Executive Officer and a director at NGM Biopharmaceuticals and also previously served as NGM’s Chief Financial Officer.

Pamela Conley, Ph.D.

Cofounder & Chief Scientific Officer

Pamela Conley, Ph.D., is Chief Scientific Officer, Founding Chief Executive Officer, and Cofounder of Nuvig Therapeutics. She has more than 30 years of biotech industry experience.

Celia Lin, M.D.

Chief Medical Officer

Celia Lin, M.D. has more than 20 years of experience across a variety of senior positions within industry and academia.

Greg Coffey, Ph.D.

Cofounder & Vice President, Immunology & Clinical Translational Research

Greg Coffey, Ph.D., has more than 17 years of experience in clinical translational research and drug development.

Bella Oguno

Vice President, Development Operations

Bella Oguno has more than 20 years of experience in clinical operations with a focus on developing high-level operational strategies and teams to execute multiple global and complex clinical trials.

Bill Avery, Ph.D.

Vice President, Nonclinical Development

Bill Avery, Ph.D., has over 23 years of biotech industry experience in preclinical and translational development.

Cindy Young, CPA

Vice President, Finance

Cindy Young has more than 25 years of experience focused on establishing strategy and leading finance at private biotech companies.

Mark Karbarz, Ph.D.

Vice President, Biologics Development & CMC

Mark Karbarz, Ph.D., has over 20 years of experience in pharmaceutical drug development with extensive experience building biotech companies.

Olga Bandman, M.D.

Vice President, Clinical Development

Olga Bandman, M.D., has more than 25 years of experience in clinical development across multiple therapeutic areas.

Yvonne Coffey

Vice President, Regulatory Affairs

Yvonne Coffey has more than 25 years of biotech experience in global regulatory affairs and drug development ranging from early development through commercialization.

Jessica Bright

Senior Director, Research Immunology

Jessica Bright has more than 25 years of experience in the biotech industry driving discovery projects from inception through preclinical development.

Joseph Leung

Senior Director of CMC Biologics Manufacturing

Joseph Leung has more than 13 years of industry experience focused on process development and manufacturing of antibodies, bispecifics, and antibody-drug conjugates.

Karen Grimm

Senior Director of Analytical Development

Karen Grimm has more than 20 years of experience in the biotech and medical device industries, with a focus on analytical development.

Heidi Remsberg

Director of Operations/HR Business Partner

Heidi Remsberg brings more than 20 years of experience in biotech and medical device start-ups with critical roles in operations.

Board of Directors

James Mackay, Ph.D.

Independent Board Chair

James Mackay, Ph.D., is CEO of Kateran Consulting with over 40 years of development and commercialization expertise in the pharmaceutical industry.

Timothy Anderson

Director

Timothy Anderson is a Managing Director with Blue Owl Capital focused on healthcare opportunities.

Tiba Aynechi, Ph.D.

Director

Tiba Aynechi, PhD., is a General Partner with Norwest Venture Partners.

Hannah Chang, M.D., Ph.D.

Director

Hannah Chang, M.D., Ph.D., is a Managing Director at Platanus.

Kenneth Harrison, Ph.D.

Director

Ken Harrison, Ph.D., is a Partner with Novo Ventures.

Paulina Hill, Ph.D.

Director

Paulina Hill, Ph.D., is a Partner with Sanofi Ventures.

Ciara Kennedy, Ph.D.

Independent Board Member

Ciara Kennedy, Ph.D., is founder, President and CEO of Sorriso Pharmaceuticals.

David J. Woodhouse, Ph.D.

Nuvig Therapeutics

David J. Woodhouse, Ph.D. has over 23 years of experience in the biopharmaceutical industry.

Advisors

Robert M. Anthony, Ph.D.

Advisor

Robert M. Anthony, Ph.D., is an Associate Professor at Harvard Medical School.

Falk Nimmerjahn, Ph.D.

Advisor

Falk Nimmerjahn, Ph.D., is a full professor and director of the Institute of Genetics at the Friedrich-Alexander University Erlangen.

Jeffrey V. Ravetch, M.D., Ph.D.

Advisor and Cofounder

Jeffrey V. Ravetch, M.D., Ph.D., is a cofounder of Nuvig Therapeutics.

Taia T. Wang, M.D., Ph.D., MSCI

Advisor

Taia Wang, M.D., PhD., MSCI, is an Associate Professor of Medicine at Stanford University.